This might explain why recombinant overexpression of BLT2 in cancer cells already expressing endogenous BLT2 have a growth advantage without any further treatment, because more receptor-binding sites (BLT2) can be stimulated by LTB4. This evidence concerns the gene LTB4R2 and cancer.